- Astiva Health’s culturally inclusive approach sets a new precedent in the Medicare Advantage market
- Enrollment in Medicare Advantage programs is projected to encompass half of all Medicare enrollments by 2024, with Astiva Health leading the charge in service expansion and inclusivity
- Astiva Health is committed to reshaping healthcare delivery with increased access to quality healthcare for diverse populations
In a landscape where more individuals are becoming eligible for Medicare, Astiva Health is carving out a niche as a rapidly growing Medicare Advantage Prescription Drug (“MAPD”) health plan. Astiva stands out by redefining personalized and comprehensive healthcare standards. Reflecting its success, Astiva recently celebrated surpassing the 10,000-member milestone (https://ibn.fm/qawEI).
“Projected increases from 31.6 million in 2023 to 33.8 million in 2024 in Medicare Advantage enrollment show that nearly half of all Medicare enrollees will choose Advantage plans,” according to a CMS release (https://ibn.fm/mtTsb).
“These statistics underscore the demand for robust and stable healthcare options,” added CMS Deputy Administrator Meena Seshamani, MD, PhD.
Astiva is at the forefront, offering robust solutions to those seeking quality Medicare options. The recent surge from 4,700 to more than 10,000 members is partly due to strategic expansion into Los Angeles, Riverside and San Bernardino counties. This expansion, effective from Jan. 1, 2024, is a crucial step in Astiva Health’s mission to offer increased access to healthcare for a wide demographic in Southern California.
“Our growth to over 10,000 members is a direct reflection of our commitment to personalized, culturally sensitive healthcare,” said Dr. Tri T. Nguyen, cofounder and CEO of Astiva Health. “By extending our services to these counties, we’re not just expanding our reach — we’re enhancing the healthcare experience for our members.”
Astiva is redefining healthcare standards by improving member services, medical care, prescription coverage, and supplemental benefits. The company also offers multilingual solutions and educational resources, ensuring all members receive effective and culturally attuned care.
“This increase in membership showcases Astiva Health’s robust, member-focused approach, building lasting relationships and meeting the unique needs of our members,” states Astiva Health. “It also reflects the community’s trust in us as their healthcare provider.”
Astiva Health is dedicated to innovative health plans that meet the unique requirements of its members, emphasizing a culturally responsive healthcare model and serving underserved populations. This not only addresses critical societal needs but positions Astiva to capitalize on significant market growth potential. Astiva Health’s goal is to foster lasting relationships and improve the overall well-being of the communities it serves.
For more information, visit the company’s website at www.AstivaHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN